MDxHealth Eyes 2016 Liquid Biopsy Prostate Cancer Test Launch With NovioGendix Buy
This article was originally published in Clinica
Belgian epigenetics specialist MDxHealth is planning to launch in the US and Europe next year a new noninvasive test to guide doctors in determining which patients are at low or high risk of prostate cancer. The test, which will help reduce unnecessary prostate biopsy procedures and their associated costs and complications, is based on technology which MDxHealth will gain through the agreed acquisition of NovioGendix, a spinout of Radboud University Medical Center in the Netherlands.
Register for our free email digests: